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Interleukin-4 (IL-4) is an immunomodulatory cytokine, which can inhibit the growth of tumour cells. Pancreatic cancer cells and tissues
express high levels of IL-4 receptors. The aim of this study was to characterise the effects of IL-4 on the growth and signalling
pathways of pancreatic cancer cells. Cell growth was determined by cell counting and MTT assays in association with fluorescence-
activated cell sorter analysis, IL-4 expression using ELISA and real-time PCR techniques, and signal transduction using
immunoprecipitation or immunoblot analysis. We now report for the first time that IL-4 significantly enhanced the growth of five
out of six cultured pancreatic cancer cell lines in a dose-dependent manner in association with an increased fraction of cells in S-
phase. Surprisingly, all six cell lines expressed endogenous IL-4, and IL-4 was detectable in the supernatant. Incubating cells with
neutralising IL-4 antibodies resulted in a significant inhibition of basal growth in three cell lines, including IL-4-unresponsive MIA PaCa-
2 cells, which however expressed the highest endogenous IL-4 levels. Interleukin-4 enhanced activity of MAPK, Akt-1, and Stat3 in IL-
4-responsive, but not in IL-4-unresponsive MIA PaCa-2 cells; however, IL-4 enhanced tyrosine phosphorylation of insulin receptor
substrate-1 and -2 in all cell lines. Our results demonstrate for the first time that pancreatic cancer cells produce IL-4 and that IL-4 can
act as a growth factor in pancreatic cancer cells. Together with the observation that neutralising IL-4 antibodies can inhibit the growth
of these cells, our results suggest that IL-4 may act as an autocrine growth factor in pancreatic cancer cells and also give rise to the
possibility that cancer-derived IL-4 may suppress cancer-directed immunosurveillance in vivo in addition to its growth-promoting
effects, thereby facilitating pancreatic tumour growth and metastasis.
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Interleukin-4 (IL-4) is a secreted, potentially glycosylated anti-
inflammatory and immunomodulatory 18kDa cytokine with
pleiotropic functions sharing several biologic activities with IL-
13. It is produced mainly by a subpopulation of activated T-cells,
TH2 CD4(þ) helper cells, and promotes the proliferation and
differentiation of activated B-cells, the expression of class II MHC
antigens, and of low-affinity IgE receptors in resting B-cells (Paul,
1991).
The biological activities of IL-4 are mediated by a specific
IL-4 receptor (IL-4R) that is expressed at densities of 100–
5000copiescell
 1 (Nelms et al, 1999). IL-4 receptor a (IL-4Ra) was
found to be expressed on solid human tumours, including
malignant melanoma, breast carcinoma, ovarian carcinoma,
mesothelioma, glioblastoma, renal cell carcinoma, head and neck
carcinoma, and AIDS-associated Kaposi’s sarcoma (Kawakami
et al, 2001; Gooch et al, 2002). It was also reported that several
cultured pancreatic cancer cell lines express IL-4Ra (Kornmann
et al, 1999a). Using binding assays, it could be demonstrated that
PANC-1 pancreatic cancer cells express high numbers of specific
IL-4 binding sites (Kawakami et al, 2002). The significance of
IL-4Rs expression in pancreatic cancer and other solid tumours is
still unknown. In contrast to its growth stimulatory effect on
lymphocytes, IL-4 has been shown to have a modest but direct
inhibitory effect on the growth of tumour cells of haematopoietic
and nonhaematopoietic origin in vitro and in vivo, including
those derived from human melanoma, non-Hodgkin’s malignant
B-lymphoma, and colon, renal, gastric, and breast carcinoma
(Defrance et al, 1992; Gallagher and Zaloom, 1992; Morisaki et al,
1992; Toi et al, 1992, Obiri et al, 1993).
The different effects of IL-4 on cell proliferation presently
remain unclear. Chang and co-workers proposed that binding of
IL-4 to its receptor can trigger at least three signalling pathways
including insulin receptor substrate (IRS)/signal transducer and
activator of transcription 3 (Stat3), Stat6, and Stat1 activation.
Whereas the activation of IRS substrates and Stat3 may result in
cell proliferation, activation of Stat6 seems to be involved in
regulation of the immune system such as T helper cell differentia-
tion and IgE class switching (Chang et al, 2000; Scholz et al, 2003).
In contrast, IL-4-mediated activation of Stat1 results in cell growth
inhibition (Chang et al, 2000).
Pancreatic cancer is a deadly disease with a poor prognosis and
a propensity to rapidly metastasise to tissues and lymph nodes
while exhibiting resistance to cancer-directed immune mechan-
isms. Pancreatic cancers not only overexpress multiple growth
factors including members of the insulin-like growth factor (IGF)
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sfamily like IGF-I (Korc, 1998), but also overexpress the intra-
cellular signal transducers of this pathway, IRS-1 and IRS-2
(Kornmann et al, 1998). Pancreatic cancer cells and tissues also
express high levels of IL-4Ra (Kornmann et al, 1999a,b; Kawakami
et al, 2002).
In view of the abundant production of IL-4 by activated T-
lymphocytes, the proclivity of pancreatic cancer to metastasise and
to avoid cancer-directed immune mechanisms, this project aimed
to characterise the effects of IL-4 and neutralising IL-4 antibodies
on the growth of cultured human pancreatic cancer cells, the
expression and secretion of IL-4 by human pancreatic cancer cells,
and IL-4-dependent signalling pathways.
MATERIALS AND METHODS
Materials
The Cycle Test Plus DNA Reagent Kit for fluorescence-activated
cell sorter (FACS) analysis was purchased from Becton Dickinson
Immunocytometry Systems (San Jose, CA, USA). Human recom-
binant IL-4 and IGF-I, 3-(4,5-methylthiazol-2-yl)-2,5-diaphenylter-
trazolium bromide (MTT), monoclonal mouse anti-b-actin
antibody, and secondary horseradish-conjugated anti-rabbit were
from Sigma Chemical Co. (St Louis, MO, USA). Rabbit polyclonal
anti-phospho-Akt antibody (Ser 473)-R (1:500), mouse mono-
clonal Akt-1 (B-1) antibody (1:500), anti-active mitogen-activated
protein kinase (MAPK) (p-ERK, E-4) mouse monoclonal antibody
(1:5000), ERK-2 (C-14) rabbit polyclonal antibody (1:2000),
mouse monoclonal IgG1 antibody p-Stat1 (A-2) (1:200), rabbit
polyclonal antibody Stat1 p84/p91 (E-23) (1:250), mouse poly-
clonal antibody p-Stat3 (B-7) (1:1000), rabbit polyclonal antibody
Stat3 (K-15) (1:200), rabbit polyclonal antibody Stat6 (1:1000),
mouse monoclonal IgG2b antibody p-Tyr (PY99) (1:2000), and
mouse whole-cell lysate from normal embryo fibroblast cells (NIH/
3T3 cells) were from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Monoclonal anti-human IL-4 antibody and mouse mono-
clonal anti-human CD5 antibody were obtained from R&D
Systems (Minneapolis, MN, USA). The human IL-4 immunoassay
kit was from BioSource International Inc. (Camarillo, CA, USA).
Rabbit immunoaffinity-purified anti-rat IRS-1 (1:2000) and rabbit
polyclonal anti-mouse IRS-2 (1:2000) were from Upstate Biotech-
nology Inc. (Lake Placid, NY, USA). The RNeasy Mini Kit for RNA
extraction was from Qiagen GmbH (Hilden, Germany). Super-
Script First-Strand Synthesis System for RT–PCR was from
Invitrogen (Carlsbad, CA, USA). The Real–Time PCR Kit for
Human IL-4 Gene Expression was from Maxim Biotech. Inc. (CA,
USA). ASPC-1, CAPAN-1, MIA PaCa-2, and PANC-1 human
pancreatic cancer cells were purchased from American Type
Culture Collection (ATCC, Rockville, MD, USA). COLO-357 and
T3M4 human pancreatic cancer cells were a gift from RS Metzgar
(Duke University, Durham, NC, USA).
Cell culture
COLO-357, MIA PaCa-2, and PANC-1 cells were grown in DME
medium, whereas ASPC-1, CAPAN-1, and T3M4 cells were grown
in RPMI-1640 medium. All media were supplemented with 8%
FBS, penicillin G (100Uml
 1), and streptomycin (100mgml
 1),
termed complete medium. Cells were maintained at 371Ci n
humidified air with 5% CO2. Medium containing antibiotics, 0.1%
BSA, 5mgl
 1 transferrin, and 5mgl
 1 selenious acid was termed
serum-free medium and used when indicated for the specific
assays.
Growth assays
For cell counting, cells (150000well
 1) were seeded in 12-well
plates in complete medium (3mlwell
 1). After 24h, the medium
was replaced by serum-free medium (500mlwell
 1) for the
indicated times in the absence or presence of IL-4 (5nM) or IGF-
I( 5n M). The medium was changed daily, including the respective
additions. For cell counting, cells were trypsinised, resuspended,
adjusted to 1ml, and counted under a light microscope using a
haemocytometer.
Cell growth was also determined by the MTT assay as described
(Kornmann et al, 1998). Cells (10000well
 1) were seeded in 96-
well plates, incubated for 24h in complete medium, and then for
48h in serum-free medium in the absence or presence of the
indicated substrates. The assay was also performed in the presence
of 8% FBS. In these cases, only 5000cellswell
 1 were seeded and
IL-4 was added after 24h for 48h. To initiate the assay, MTT
reagent was added and cells were incubated for an additional 4h at
371C. After removal of the medium and dissolving the crystals with
acidified isopropanol, the samples were analysed using an ELISA
plate reader at 570nm. The value at 650nm was subtracted as
background.
Cell cycle analysis: fluorescence-activated cell sorter
To determine the effect of IL-4 and IGF-I on cell cycle, cells were
seeded in six-well plates, incubated for 24h in complete medium to
60% confluency, and then serum starved for 24h. The medium was
replaced by serum-free medium in the absence or presence of IL-4
(5nM) or IGF-I (5nM) for another 24h. Thereafter, FACS analysis
was performed using a CycleTest Plus kit according to the
instructions of the manufacturer and FACScan (Becton Dickinson)
analysis system equipped with a FACStation, MAC PowerPC
computer, and CellQuest acquisition software as previously
described (Kornmann et al, 1999a,b).
Interleukin-4 ELISA
Total cell lysates were prepared as described (Kornmann et al,
1998). After adjusting the protein concentration using lysis buffer,
100ml aliquots were used for the IL-4 sandwich ELISA carried out
according to the protocol of the manufacturer. To detect IL-4 in
the supernatant, cells were cultured in six-well plates to 70%
confluency. After washing, cells were cultured in 1ml of serum-free
medium including proteinase inhibitors (Kornmann et al, 1998)
for 48h. The medium was then harvested and centrifuged before
subjecting 100ml aliquots to the ELISA. Cells were counted to
determine the amount of IL-4 secreted per cell. In the present
study, the interassay variability was less than 28% and the intra-
assay variability less than 5%.
Analysis of IL-4 mRNA
Exponentially growing cells were harvested and pelleted by
centrifugation at 300g for 5min after washing twice with PBS.
Total RNA extraction and reverse transcription was then
performed according to the instructions of the manufacturer.
The design of the IL-4 50 and 30 primers was based on the
sequence with GenBank accession number NM_000589. The design
of b-actin 50 and 30 primers was based on the sequence with
GenBank accession number NM_001101. Primer sets for IL-4 and
FRET probes for IL-4 with known cDNA copy number were
designed to generate an 81bp PCR product as described by the
manufacturer (Maxim Biotech Inc., CA, USA). Primers for b-actin
were sense GGCATCCTCACCCTGAAGTA and antisense
GTCAGGCAGCTCGTAGCTCT resulting in a 525bp PCR product.
Real-time RT–PCR amplification was performed using the
QuantiTectt SYBR Green PCR Kit (QIAGEN, Germany). Prior to
quantitative analysis, several titration experiments, for MgCl2, and
efficiency tests were performed to determine optimum amplifica-
tion conditions. Standard curves containing a specific number of
cDNA copies were generated for the IL-4 gene transcript. After the
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Diagnostics, Mannheim, Germany) automatically converted the
raw data into copies of target molecules using standard curves.
In brief, the total reaction volume for each sample was 20ml and
contained 2ml cDNA solution, 10pmol of each primer, 100mM of
each 2-deoxynucleotide 50-triphosphate, 4mM MgCl2, and 1U of
Taq polymerase and Syber Green as indicator. After hot activation
at 941C for 15min, 55 cycles of 15s denaturation at 941C, 25s
annealing at 681C, and 16s synthesis at 721C were performed. The
colour signal (Syber Green, which combines exclusively to the
double-stranded DNA) was measured in a real-time model at the
end of the DNA synthesis phase, and the crossing point (where the
colour signal began to increase exponentially) was calculated. The
specificity of DNA amplification was examined with analysis of the
melting curve. Samples with known cDNA copy number were used
as a positive control for IL-4 PCR, and no RT cDNA samples and
samples without cDNA (water) served as negative controls.
Immunoblot analysis
Cells were cultured to 80% confluency and then serum starved for
18h prior to the analysis including growth factors followed by
immunoblot analysis with the respective primary and secondary
antibodies as described (Kornmann et al, 1999a,b). To confirm an
equal transfer of the proteins to the membranes, stripping of the
membranes was performed when indicated using 50ml of
stripping buffer for 30min in a water bath at 501C (Kornmann
et al, 1999b).
Immunoprecipitation
Insulin receptor substrate immunoprecipitation assays were
carried out as previously described (Kornmann et al, 1998). Cells
were grown to 80% confluency and serum starved for 18h before
the respective treatment. After cell lysis using a modified RIPA
buffer (Kornmann et al, 1998), lysates (1000mg1000ml
 1) were
incubated for 2h at room temperature with 4mg of the respective
antibody (4mg IRS-1 or 4mg IRS-2) on a rotator followed by 45min
incubation after adding 50ml of slurry protein A sepharose. For
subsequent antiphosphotyrosine immunoblot analysis, precipi-
tates were washed three times with ice-cold PBS, resuspended in
50mlo f2  Laemmli buffer, and boiled for 5min at 1001C before
the analysis. Desired volumes (20ml) were transferred to PAGE–
SDS minigels followed by immunoblot analysis.
Statistics
Results are expressed as mean7s.e.m. or mean7s.d. When
indicated, Student’s t-test or Mann–Whitney rank sum test was
used for statistical analysis using SigmaStat statistical software.
Po0.05 was taken as the level of significance (two-sided).
RESULTS
Effects of IL-4 on pancreatic cancer cell proliferation
Human IL-4 exerted a dose-dependent increase on the growth of
five pancreatic cancer cell lines under serum-free conditions
(Figure 1A). Neither an increase of the IL-4 concentration to 10nM
nor a prolongation of the incubation period to 72h results in an
enhanced proliferation compared to 5nM IL-4 for 48h (data not
shown). Interleukin-4 (5nM) did not alter the growth of MIA PaCa-
2 cells (572.4% s.e.m.). IL-4 (5nM) enhanced the growth of ASPC-
1 and COLO-357 cells by 31% (77.5% s.e.m.) and 16% (71.3%
s.e.m.), respectively, under similar conditions in the presence of
10% serum (Po0.02). The growth of CAPAN-1 (2579.8% s.e.m.)
and PANC-1 (1472.2% s.e.m.) was also enhanced in the presence
of 10% serum, but these effects were not significant (n¼3). Similar
to the serum-free conditions, the growth of MIA PaCa-2 cells was
not altered by IL-4 (5nM) in the presence of 10% serum
( 8.774.9% s.e.m.).
To confirm the results obtained by MTT assay suggesting
that IL-4 can act like a growth factor in pancreatic cancer cells,
cell counting and comparison with the growth-promoting effects
of IGF-I was performed next in PANC-1 cells. Interleukin-4
(5nM) resulted in an increase in cell number in PANC-1 during
the whole 4-day incubation period. The maximal increase in
proliferation for IL-4 was observed on day 3, resulting in a 39%
(73.5% s.e.m.) increase in cell number (Figure 1B). For IGF-I,
a well-known potent mitogenic growth factor, a maximal increase
in cell number was observed also on day 3, resulting in a 76%
(711% s.e.m.) increase in cell number (Figure 1B). Flow cyto-
metric analysis revealed that the enhanced proliferation of
PANC-1 cells in the presence of IL-4 was associated with a marked
increase in the number of cells in S phase comparable to IGF-I
(Figure 1C).
Expression of IL-4 in human pancreatic cell lines
In view of the mitogenic effects of IL-4, we next sought to
determine whether these cells express this cytokine. Determined by
ELISA, the IL-4 protein was detectable in total cell lysates from all
six tested cell lines (Figure 2A). Relatively high IL-4 protein levels
were found in lysates prepared from COLO-357 and MIA PaCa-2
cells and relatively low IL-4 protein levels were found in lysates
prepared from PANC-1 and T3M4 cells (Figure 2A). A subsequent
analysis of serum-free medium revealed that IL-4 could also be
detected in the supernatant of all six cell lines. Mean7s.d.
(pgml
 110
 5 cells) IL-4 protein concentrations in the supernatant
were 1.070.7, 0.970.3, 1.170.9, 1.570.6, and 2.570.2 for ASPC-
1, CAPAN-1, COLO-357, MIA PaCa-2, and T3M4 cells, respectively.
Relatively high IL-4 concentrations were detectable in PANC-1
cells (5.371.7 s.d. (pgml
 110
 5 cells)).
Real-time PCR analysis using specific primers for the IL-4-
encoding sequence revealed the presence of IL-4 mRNA transcripts
in all six cell lines. Interleukin-4 mRNA levels correlated with IL-4
protein levels after normalisation to b-actin used as internal
reference gene in four cell lines; however, relatively high IL-4
mRNA levels and relatively low protein levels were found in
CAPAN-1 and especially in PANC-1 cells (Figure 2B).
Effects of neutralising IL-4 antibodies on cell growth
To determine whether there is a potential for IL-4-mediated
autocrine growth stimulation, cells were incubated with increasing
concentrations of an IL-4 neutralising antibody. The basal growth
of COLO-357 and PANC-1 cells was slightly inhibited in a dose-
dependent manner, with maximal inhibition of 13% (72.0%
s.e.m.) and 10% (72.4% s.e.m.), respectively, occurring at
10mgml
 1 of the anti-IL-4 antibody (Figure 3). The effects were
minor, but reproducible (n¼7 for PANC-1 and n¼10 for COLO-
357). Interestingly, the basal growth of IL-4-unresponsive MIA
PaCa-2 cells, which express high endogenous IL-4 levels, was
also inhibited in the presence of IL-4 neutralising antibodies by
17% (74.19% s.e.m.). A CD5 control antibody (10mgml
 1) only
slightly altered the growth of the six cell lines.
In order to test the specificity of this antibody, the effects of the
IL-4 neutralising antibody on cell growth in the presence of
exogenous IL-4 were examined. Interleukin-4-stimulated growth
(5nM) of COLO-357 cells was significantly inhibited by incubation
with 10mgml
 1 of neutralising IL-4 antibody. This antibody also
attenuated the effects of exogenous IL-4 (5nM) in the other tested
cell lines; however, the effect did not reach significance (Figure 3),
demonstrating that this antibody can at least partially block IL-4-
mediated proliferative effects.
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Intracellular signalling of IL-4 is mediated via Janus kinases
(JAKs), cytoplasmic protein tyrosine kinases that associate with
the receptor complex and phosphorylate the receptor as well as
other substrates recruited to the receptor complex. First, the IL-4-
dependent tyrosine phosphorylation of IRS-1 and -2, over-
expressed in human pancreatic cancer, was analysed. Similar to
IGF-I, IL-4 (5nM for 5min) induced tyrosine phosphorylation of
IRS-1 and IRS-2 in PANC-1 (Figure 4A) and the other four IL-4-
responsive cell lines (not shown). It also induced tyrosine
phosphorylation of IRS-1 in MIA PaCa-2 cells unresponsive to
exogenous IL-4 (Figure 4A). In MIA PaCa-2 cells, which express
only low levels of IRS-2 (Kornmann et al, 1998), no clear
enhancement of IRS-2 tyrosine phosphorylation could be demon-
strated.
Mitogen-activated protein kinases mediate mitogenic signalling
of several growth factors including IGF-I and cytokines. Both IL-4
and IGF-I enhanced MAPK activity in IL-4-responsive COLO-357
cells (Figure 4B). This effect was less pronounced for IL-4 in
comparison to IGF-I, but reproducible (n¼3), and was also
observed in the other IL-4-responsive cell lines (not shown). In
contrast, in IL-4-nonresponsive MIA PaCa-2 cells, IGF-I, but not
IL-4, enhanced MAPK activity (Figure 4B).
Akt is activated by insulin, various growth factors, and survival
factors, and functions in a wortmannin-sensitive pathway invol-
ving PI-3 kinase (Franke et al, 1997). Both IL-4 and IGF-I
enhanced Akt activity in IL-4-responsive COLO-357 cells
(Figure 4C) and in the other IL-4-responsive cell lines (not
shown). Also the activation of Akt was less pronounced for IL-4 in
comparison to IGF-I, but reproducible (n¼3). In IL-4-nonre-
sponsive MIA PaCa-2 cells, IGF-I, but not IL-4, enhanced Akt
activity (Figure 4C).
Expression and activation of Stat by IL-4
In addition to IRS-1 and IRS-2, IL-4 has been reported to be able to
activate the transcription factors Stat1, Stat3, and Stat6. At first, we
examined whether pancreatic cancer cell lines express Stat1, Stat3,
and Stat6. The Stat1 protein was expressed in all six cell lines at
various levels (Figure 5A). Highest levels of Stat1 (85kDa) were
observed in MIA PaCa-2 cells. The Stat3 immunoblot analysis
revealed a band of 92kDa readily visible in CAPAN-1, MIA PaCa-2,
and PANC-1 cells corresponding to the Stat3a isoform. A very faint
Stat3 band was also detectable in the other cell lines after a long
exposure; Stat6 (120kDa) was also expressed in pancreatic cancer
cells at various levels, with the highest levels found in COLO-357
cells (Figure 5A).
Phosphorylation of Stat occurs in response to a broad spectrum
of physiologic stimuli, including activation of cytokine receptors
and receptor-tyrosine kinases. Next, we examined activation of
Stat1, Stat3, and Stat6 after incubation with IL-4 by immuno-
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Figure 1 Effect of IL-4 on pancreatic cancer cell growth and cell cycle
distribution. (A) IL-4 dose–response. Indicated cells were cultured in 96-
well plates in the absence and presence of increasing concentrations of IL-4.
Cell growth was determined by the MTT assay after 48h. Results are
expressed as growth (in %) of the corresponding untreated controls and
are the means (7s.e.m.) of quadruplicate determinations from at least
three separate experiments. (B) IL-4 and IGF-I time course. PANC-1 cells
were cultured in the absence and presence of 5nM IL-4 (solid line, circle) or
5n M IGF-I (long dash line, triangle) for the indicated times. Cell growth was
determined by cell counting. Results are expressed as cell number (in %) of
untreated controls and are means (7s.e.m.) of triplicate determinations
from at least three separate experiments. (C) Effect of IL-4 and IGF-I on
cell cycle distribution. PANC-1 cells were cultured in the absence or
presence of 5nM IL-4 (open bars) or 5nM IGF-I (hatched bars) for 24h
followed by FACS analysis. Results are shown as relative difference of cell
cycle fractions in % compared to the corresponding untreated controls and
are means (7s.d.) of at least five separate experiments. *Po0.05
compared to untreated controls.
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enhanced Stat3 phosphorylation in IL-4-responsive COLO-357
cells (Figure 5B) and other IL-4-responsive cells (not shown), but
not in IL-4-nonresponsive MIA PaCa-2 cells (Figure 5B). We did
not observe an increase of Stat1 or Stat6 phosphorylation on
incubating any of the cell lines with IL-4 even after long exposure
and using positive phosphorylation controls provided by the
manufacturer (not shown).
DISCUSSION
Interleukin-4 is an anti-inflammatory cytokine involved in
various immune responses (Nelms et al, 1999). Nevertheless, in
addition to its expression and functions in immune cells, IL-4Ra
receptors were found to be widely expressed on solid human
tumours including pancreatic cancer (Kawakami et al, 2001).
Initially, it was hypothesised on the basis of upregulation of
IL-4R molecules in malignant tumours of epithelial origin that
IL-4R may be a product of an oncogene that could be involved
in the process of carcinogenesis (Al Jabaari et al, 1989). However,
in most of the examined tumour cell lines, IL-4 induced
growth inhibition (Hoon et al, 1991; Gallagher and Zaloom,
1992; Morisaki et al, 1992; Toi et al, 1992, Obiri et al, 1993). Only
in Burkitt’s lymphoma (Chang et al, 2000), in three of 35 malig-
nant B-samples (Taylor et al, 1990), and in human head and
neck squamous cell carcinoma cells (Myers et al, 1996), IL-4
was reported to stimulate cell proliferation. The present study
revealed for the first time that IL-4 also exerts proliferative
effects in the majority of pancreatic cancer cell lines. Flow
cytometry and cell counting in comparison to the potent mito-
genic growth factor IGF-I revealed that IL-4 is less potent, but
exerts effects similar to IGF-I in increasing cell number and
S-phase fraction.
Myers et al (1996) proposed a possible explanation for the
disparity in the observed effects of IL-4 on the growth of tumour
cell lines. Various IL-4R-expressing tumour types may have
different downstream mediators of IL-4 action. To date, a number
of cytoplasmic signalling proteins have been shown to be
phosphorylated in response to IL-4R stimulation, including Jak1,
Stat1, Stat3, Stat6, IRS-2, and others (Zamorano and Keegan, 1998;
Nelms et al, 1999; Chang et al, 2000).
Insulin receptor substrate proteins are large adaptor PTB
domain proteins involved in insulin and IGF-1 signalling
(White and Yenush, 1998); IRS-2, in particular, was also identi-
fied as one of the predominant proteins phosphorylated in
response to IL-4 (Sun et al, 1995). Recruitment of IRS-2 to the
activated IL-4Ra chain results in its phosphorylation and
subsequent activation of downstream signalling proteins, includ-
ing phosphatidylinositol-3 (PI-3) kinase (Sun et al, 1995). We
have shown that both IGF-I and IL-4 induced the tyrosine
phosphorylation of IRS-1 and IRS-2 in five IL-4-responsive cell
lines. Interestingly, IL-4 also induced the tyrosine phosphory-
lation of IRS-1 in IL-4-unresponsive MIA PaCa-2 cells, demons-
trating that the initial IL-4 signal transduction is functional in MIA
PaCa-2 cells.
The MAPK and Akt pathways are also key components in
the signal transduction of many mitogenic growth factors such as
IGF-I and are known to regulate proliferation and apoptosis
in different cancers. They are classically activated following
ligand–receptor interaction by the sequential activation of a
linear cascade of protein kinases, including Ras, Raf-1, MEK, and
the MAPKs ERK-1 and ERK-2 (Puri and Siegel, 1993; Smerz-
Bertling and Duschl, 1995) on the one hand and PI 3-kinase and
Akt on the other hand (Franke et al, 1997; Fahy et al, 2003).
Activation of the MAPK and Akt cascades has been observed for
several other cytokines, including IL-3, IL-12, and IL-13. In the
present study, we demonstrated for the first time that IL-4
activates MAPK and Akt in IL-4-responsive pancreatic cancer
cells. In IL-4-nonresponsive MIA PaCa-2 cells, IGF-I but not
IL-4 enhanced MAPK and Akt activity, suggesting that MAPK
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Figure 2 Interleukin-4 expression in pancreatic cancer cells. (A)
Interleukin-4 ELISA. Total cell lysates (100mg) of indicated cells were
subjected to IL-4 sandwich ELISA. Results are shown as IL-4 protein
concentration per mg of the corresponding total cell lysate and are means
(7s.d.) of three separate determinations. IL-13 (500ng) and lysis buffer
alone were used as negative controls. (B) Interleukin-4 real-time RT–PCR.
After reverse transcription, IL-4-specific real-time PCR was performed
using b-actin as the housekeeping gene. Results are shown as IL-4 mRNA
copy number normalised to b-actin and are means (7s.d.) of three
separate determinations. No RT samples (PANC-1) and water alone
served as negative controls.
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sand Akt activation are essential for IL-4-induced cell proliferation
in pancreatic cancer cells.
Interleukin-4 may exert various effects dependent on the
activation of specific Stat transcription factors as proposed by
Chang et al (2000). All human pancreatic cancer cells tested
expressed various levels of Stat1, Stat3, and Stat6 proteins.
However, IL-4-induced activation was only observed for Stat3 in
IL-4-responsive cells similar to MAPK and Akt, while in IL-4-
nonresponsive cells, IL-4 did not induce phosphorylation of Stat3.
This finding is especially exciting in regard to the recently
published results of Scholz et al (2003), demonstrating that
activated Stat3 can promote the malignant phenotype of human
pancreatic cancer by acceleration of G1/S-phase progression and
thus supporting our present results.
The unresponsiveness of MIA PaCa-2 cells to exogenous
IL-4 remains to be determined. However, there are several
possible explanations. First, as shown by Northern blot analysis,
MIA PaCa-2 cells express lowest levels of IL-4Ra (Kornmann et al,
1999a). In association with the high endogenous IL-4 levels,
this may result in unresponsiveness to exogenous IL-4. This is
also supported by the observation that neutralising IL-4 anti-
bodies significantly inhibited the basal growth of MIA PaCa-2
cells. Second, MIA PaCa-2 cells have shown only a slight activa-
tion of IRS-2 as compared to the other cell lines resulting
in subsequent nonactivation of the MAPK, Akt, and Stat3 path-
ways. Additional other alternative pathways, however, cannot
be ruled out at this point. It is also possible that the expression
of the IL-13Ra1 chain, which associates with the IL-4Ra chain
to form a functional receptor, may influence the effects of
exogenous IL-4 although MIA PaCa-2 cells as well as the other
pancreatic cancer cells lines express IL-13Ra1 (Kornmann et al,
1999a).
Our present study not only demonstrated that IL-4 can exert
growth stimulatory effects in pancreatic cancer cells but that they
themselves express different amounts of IL-4. To our knowledge,
this is a novel finding, which has thus far only been demonstrated
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Figure 3 Effect of IL-4 and neutralising IL-4 antibodies (NIL-4) on pancreatic cancer cell growth. Indicated cells were seeded in 96-well plates and
incubated in the absence or presence of increasing concentrations of IL-4 neutralising antibodies (mg) alone, IL-4 (5nM), or the combination of NIL-4 (10mg)
and IL-4 (5nM). Cell growth was assessed after 48h by MTT assay. Results are expressed as growth in % of the corresponding untreated controls and are the
means (7s.e.m.) of quadruplicate determinations from at least three separate experiments. (*) Po0.05 compared to untreated controls. (1) Po0.05
compared to IL-4-treated cells.
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sin lymphoma cells (Taylor et al, 1990; Ford et al, 1993). Several
lines of evidence in our study suggest that IL-4 has the potential to
exert autocrine growth stimulatory effects. First, IL-4 stimulated
growth of five pancreatic cancer cell lines. Second, pancreatic
cancer cells expressed IL-4. Third, anti-IL-4 neutralising anti-
bodies partially inhibited basal and IL-4-stimulated growth.
Together with the observation that pancreatic cancer cells express
high levels of IL-4Rs (Kornmann et al, 1999a), our results raise the
possibility that IL-4 may have a dual effect in human pancreatic
cancers. First, IL-4 may act as an autocrine growth factor in
pancreatic cancer cells. Second, cancer cell-derived IL-4 may exert
paracrine functions on surrounding infiltrating immune cells,
inhibiting immune responses.
Overall, our observations may help to better understand the
pathobiology of pancreatic cancer in the future giving rise to the
possibility that IL-4 and other related cytokines may be important
suppressors of cancer-directed immunosurveillance in addition to
their growth-promoting effects, thereby facilitating primary
pancreatic tumour growth and metastasis. However, to confirm
this hypothesis, further studies are necessary.
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Figure 4 Effect of IL-4 and IGF-I on IRS tyrosine phosphorylation, and
MAPK and Akt activation. Indicated cells were serum starved for 18h
before the respective treatment in the absence ( ) or presence (þ) of IL-
4( 5 n M) or IGF-I (5nM) for 5min. (A) IRS-1 and IRS-2 tyrosine
phosphorylation. Immunoprecipitation (IP) of total cell lysates (1mgml
 1)
) was carried out with IRS-1 or IRS-2 antibodies (4mgsample
 1), followed
by immunoblot analysis (IB) using a phosphor-tyrosine antibody (p-Tyr).
(B) Mitogen-activated protein kinase and (C) Akt activation in IL-4-
responsive COLO-357 and IL-4-nonresponsive MIA PaCa-2 cells.
Immunoblot analysis of total cell lysates was carried out with specific
antibodies detecting phosphorylated forms of ERK-1 and ERK-2 (p-MAPK,
B) or Akt-1 (p-Akt, C) in each upper panel. To confirm specificity and
equal loading (lower panels), membranes were stripped and reprobed with
a pan-ERK-2 antibody (ERK-2, B) or a pan-Akt-1 antibody (Akt-1, C).
Molecular weight markers are indicated on the left.
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Figure 5 Expression of Stat protein and IL-4-induced Stat phosphoryla-
tion in pancreatic cancer cells. (A) Stat1, 3, and 6 expression. Immunoblot
analysis of total cell lysates was carried out with specific antibodies
detecting indicated Stat proteins. (1) ASPC-1, (2) CAPAN-1, (3) COLO-
357, (4) MIA PaCa-2, (5) PANC-1, (6) T3M4 cells. (B) Effects of IL-4 on
Stat3 phosphorylation. Indicated cells were serum starved for 18h before
treatment in the absence ( ) or presence (þ) of IL-4 (5nM) for 5min.
Immunoblot analysis of total cell lysates was carried out with specific
antibodies detecting the phosphorylated forms of Stat3. A sample with
known Stat3 phosphorylation was used as a positive control. b-Actin
served as a loading control (lower panel). Molecular weight markers are
indicated on the left.
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